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OBJECTIVES This phase I study attempted to report the initial safety and efficacy results of transcatheter
closure of perimembranous ventricular septal defects (PmVSDs) using the new Amplatzer
Membranous VSD Occluder (AGA Medical Corp., Golden Valley, Minnesota) in the U.S.
BACKGROUND The most common congenital heart disease is PmVSD. Surgical repair is widely accepted, but
still carries a small but definite risk of morbidity and mortality.
METHODS Between October 2003 and August 2004, a total of 35 patients with PmVSD underwent an
attempt of transcatheter closure under transesophageal and/or intracardiac echocardiographic
guidance. The median age was 7.7 years (range, 1.2 to 54.4 years) and median weight was 25
kg (range, 8.3 to 110 kg). The median Qp/Qs ratio was 1.8 (range, 1 to 4), and the median
VSD size as assessed by echocardiography was 7 mm (range, 4 to 15 mm).
RESULTS The attempt to place a device was successful in 32 patients (91%). The median device size
used was 10 mm (range, 6 to 16 mm). The complete closure rates by echocardiography at 10
min (transesophageal/intracardiac), 24 h, 1 month, and 6 months (transthoracic) were 47%
(15/32), 63% (20/32), 78% (25/32), and 96% (27/28), respectively. The median fluoroscopy
time was 36 min (range, 14 to 191 min), and the median total procedure time was 121 min
(range, 67 to 276 min). Three patients (8.6%) had serious adverse events of complete heart
block, peri-hepatic bleeding, and rupture of tricuspid valve chordae tendineae. No other
patient encountered serious adverse events during the follow-up.
CONCLUSIONS Transcatheter closure of a PmVSD is technically feasible and seems safe enough in children
over 8 kg in weight to warrant continuation of clinical trials to assess the long-term safety and
efficacy. (J Am Coll Cardiol 2006;47:319–25) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.028Cardiology Foundation
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centricular septal defect (VSD) is the most common
approximately 20%) congenital heart disease (1). About
0% of these defects are perimembranous (PmVSD), in-
olving the membranous septum and the adjacent area of
uscular septum. Traditional treatment if necessary is
urgical repair, which has been widely accepted with mini-
al mortality but still carries potential risks of complete
eart block, chylothorax, phrenic nerve injury, early and late
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orporation.t
Manuscript received March 22, 2005; revised manuscript received August 20, 2005,
ccepted September 8, 2005.rrhythmias, postpericardiotomy syndrome, wound infec-
ion, and neurologic sequelae of cardiopulmonary bypass
2–5). Moreover, the sternotomy scar may be a cosmetic
oncern for the patients and their parents.
Since 1987, the Rashkind and buttoned devices have been
sed to close PmVSDs, which were originally designed for
atent ductus arteriosus and atrial septal defect, respectively
6–9). The major drawbacks of these devices were the large
elivery sheaths (11-F) required, complex implantation
echniques, inability to reposition and redeploy the device,
nterference with the aortic and tricuspid valves and signif-
cant residual shunts (25% to 60%) (6–10). The Amplatzer
embranous VSD Occluder (AGA Medical Corp.,
olden Valley, Minnesota) is the only device that is
pecifically designed for PmVSDs (11). Its initial use in six
atients in 2002 was associated with complete closure in all
nd absence of significant complications (12). After that,
everal centers reported similar encouraging results of initial
omplete closure rates of 90% to 92% (13–16). However,
hey were all reports with limited case numbers. The
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Transcatheter Closure of Perimembranous VSD January 17, 2006:319–25urpose of this phase I study was to report the initial safety
nd efficacy results of transcatheter closure of PmVSD using
he new Amplatzer Membranous VSD Occluder (AGA
edical Corp.) in the U.S.
ETHODS
tudy population. This study was conducted as a prospec-
ive, nonrandomized, phase I clinical trial involving seven
ardiac centers in the U.S. The study was approved by the
nstitutional review board of each participating center and
y the U.S. Food and Drug Administration under a
ponsor-initiated Investigational Device Exemption. All
nvestigators were selected, qualified, and trained and a
onitor was used to oversee the compliance with the study
rotocol.
The inclusion criteria of patients included: 1) PmVSD as
hown by echocardiography, and 2) symptoms of heart
ailure or evidence of left atrial and or left ventricular
nlargement for body surface area. Exclusion criteria in-
luded: 1) body weight 8 kg, 2) subaortic rim as shown by
chocardiography in the long-axis view 2 mm, 3) left
entricle to right atrial shunting, 4) right to left shunting
hrough the defect, 5) PmVSD with an aneurysm and
ultiple shunts that could not be successfully closed with
ne device, 6) sepsis, 7) complex heart lesions such as
etralogy of Fallot, 8) contraindication to antiplatelet ther-
py, 9) patients unable to be followed up for the duration of
he trial, and 10) inability to obtain informed consent.
Between October 2003 and August 2004, a total of 35
atients (23 male, 12 female) underwent an attempt at
ranscatheter device closure (Table 1). Among them were 3
Abbreviations and Acronyms
AR  aortic regurgitation
ICE  intracardiac echocardiography
PmVSD  perimembranous ventricular septal defect
TEE  transesophageal echocardiography
TTE  transthoracic echocardiography
able 1. Data for 35 Patients Who Underwent the Attempt of
ranscatheter Closure of Perimembranous VSD
Median Range
ge (yrs) 7.7 1.2–54.4
eight (kg) 25 8.3–110
chocardiography
Subaortic rim (mm) 3 2–12
VSD size (mm) in TEE (n  30)
or ICE (n  5)
7 4–15
atheterization
VSD size (mm) in LVG 7.7 4–11.7
Qp/Qs 1.8 1–4
PA systolic pressure (mm Hg) 32 15–70
PA mean pressure (mm Hg) 19 9–47
CE  intracardiac echocardiography; LVG  left ventriculography; PA  pulmo-a
ary artery; Qp/Qs  pulmonary to systemic flow ratio; TEE  transesophageal
chocardiography; VSD  ventricular septal defect.9%) patients with postoperative residual VSDs, 16 (46%)
atients had aneurysm formations around the VSDs, and 11
atients had associated other congenital heart diseases,
ncluding patent foramen ovale in 4, pulmonary valvular
tenosis/dysplasia in 3, bicuspid aortic valve in 2, small
uscular VSDs in 1, patent ductus arteriosus in 1, mild
bstein anomaly of the tricuspid valve in 1, and dextrocardia
ith situs inversus in 1. Trivial and mild aortic regurgitation
ith no aortic valve prolapse before the procedure was noted
n nine (25.7%) patients. Six patients had congestive heart
ailure, three had recurrent respiratory infections, three had
ailure to thrive, two had pulmonary hypertension, one had
yanosis attributable to her underlying cardiac anatomy of
orrected transposition and right-to-left shunt at the atrial
evel, and one had palpitations.
ata collection. Data were collected prospectively at the
ime of the procedure at each participating center by the
esponsible investigator and submitted to a central database
t the Clinical Research Division of AGA Medical Corp.
ata collected included demographic details (date of pro-
edure, age, gender, height, weight), symptoms/signs (con-
estive heart failure, failure to thrive, recurrent respiratory
ract infections, sepsis, heart murmur), electrocardiography
left atrial enlargement, left ventricular hypertrophy, rhythm
bnormality), chest X-ray (cardiomegaly, increased pulmo-
ary vascularity), echocardiography (VSD size, left atrial
nd-systolic dimension, left ventricular end-diastolic di-
ension, associated anomalies), and procedure details (an-
sthesia method, echocardiographic guidance, access route,
heath size, heparin, fluoroscopy time, procedure time). For
ny adverse event occurring during the clinical trial, the
nvestigator reported the information regarding the circum-
tances, treatment, and outcome to the sponsor. A Data
afety Monitoring Board determined whether the adverse
vents were serious adverse events, adverse events or obser-
ations, device or procedure related, and anticipated or
nanticipated. A serious adverse event was defined as an
vent that resulted in death or long-term sequelae (effects or
reatment lasting longer than six months). Potentially life-
hreatening events were also included in this group. Serious
dverse events included but were not limited to death during
r after the procedure because of complications of the
rocedure, cerebral or pulmonary embolism, bacterial endo-
arditis, device embolization that required surgical removal,
ersistent cardiac arrhythmia that required long-term med-
cal treatment (6 months) or pacemaker placement, on-
oing hemolysis that required more than one blood trans-
usion, other ongoing therapy or device removal, thrombosis
hat required thrombolytic therapy, any event that required
cute resuscitation, and any persistent (30 days) increase
n valvar regurgitation of two grades or more, or new or
orsened valvar regurgitation that required drug treatment.
vents that required surgical repair (i.e., arterial pseudoan-
urysm) or significantly prolonged hospitalization (i.e.,
ound infection) were also considered in this category. Andverse event was defined as those events that required
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January 17, 2006:319–25 Transcatheter Closure of Perimembranous VSDedical intervention but that were not life threatening, did
ot have long-term (6 months) sequelae, and did not
equire long-term (6 month) therapy. These events in-
luded but were not limited to loss of peripheral pulse
transient or required only heparin therapy); cardiac ar-
hythmia that required cardioversion or medication; blood
ransfusion because of blood loss; persistent (30 days) new
r increased valvar regurgitation; hematoma of the groin;
alvar, device, or intracardiac thrombus without emboliza-
ion and not treated with thrombolytic medication; and
evice embolization with transcatheter removal.
All other adverse events were considered observations.
he accuracy of the submitted data was verified for each
articipating institution using source documents (catheter
eports, case notes, medical records) that were analyzed by
onitors from the sponsor during control visits to these
nstitutions.
easured outcome parameters. Procedure success was
efined by device release in the appropriate position without
mbolization. The residual shunt was classified as trivial
width of the color jet as assessed by color Doppler echo-
ardiography as it exited the septum of 1 mm), small
width of 1 to 2 mm), moderate (width of 3 to 4 mm) or
arge (width 4 mm), in a way similar to the protocol
eported by Boutin et al. (17) for shunt assessment after
evice closure of atrial septal defects. Experienced echocar-
igure 1. (A) Left ventriculography in the left anterior oblique view showin
oy. (B) Cine image showing the arteriovenous loop. (C) Left ventricular d
entricular disk. (E) Cine image immediately after the right ventricular di
efore its release. (G) Cine image after the device has been released. The p
H) Final left ventriculography indicating good device position and no resiographers at the echocardiography core laboratory (based dt the sponsor’s headquarters) verified the pre-closure,
losure, and post-closure echocardiograms.
he device. The Amplatzer Membranous VSD Occluder
AGA Medical Corp.) is a self-expandable double-disk
evice made of a nitinol wire mesh. The details of the device
escription were previously reported (12).
losure protocol. The protocol used has been described in
etail in previous reports (11,12). Briefly, access was ob-
ained in the femoral artery (4- to 5-F sheath) and the
emoral vein (7- to 9-F sheath). Heparin was given to keep
n activated clotting time of 250 s. Routine right and left
eart catheterizations were performed to assess the degree of
hunting and to evaluate pulmonary vascular resistance. Left
entriculography in the long axial oblique view (60° left
nterior oblique/20° cranial) defined the location and size of
he VSD. The appropriate device size was chosen to be at
east 1 to 2 mm larger than the VSD size as measured by
olor Doppler echocardiography or ventriculography.
ransesophageal echocardiography (TEE) and/or intracar-
iac echocardiography (ICE) were used to guide and mon-
tor the procedure. Figures 1 and 2 show the various steps of
losure by cine fluoroscopy and echocardiography, respec-
ively. The follow-up protocol included physical examina-
ion and electrocardiogram and echocardiography at 10 min
TEE/ICE), pre-discharge, one month, and six months
transthoracic echocardiography [TTE]) after the proce-
-mm perimembranous ventricular septal defect (arrow) in a 22-month-old
as been deployed. (D) Left ventriculography showing good position of left
s been deployed. (F) Left ventriculography showing good device position
m marker is pointed to the apex (arrow), indicating good device position.
shunt.g a 9
isk h
sk haure. Chest X-ray was required before discharge and 24 h
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Transcatheter Closure of Perimembranous VSD January 17, 2006:319–25fter the procedure. Patients were routinely maintained on
spirin 3 to 5 mg/kg daily or equivalent antiplatelet therapy
or six months. Patients were instructed to receive infective
ndocarditis prophylaxis when needed until complete clo-
ure was documented at the six-month follow-up visit.
tatistical analysis. Medians and ranges were calculated
or individual parameters, and the differences between the
aseline and follow-up Z scores of left atrial and left
entricular dimensions were assessed by paired t test.
hanges in categorical variables were compared using a
aired sign test. A p value of 0.05 was considered
tatistically significantly. No corrections were made for
ultiple comparisons.
ESULTS
rocedural data. General anesthesia was used in 31 (89%)
atients and conscious sedation in 4 (11%). The right
emoral vein was mainly used for the venous access, and in
wo patients, both veins were cannulated. The transhepatic
ccess was used in one patient because of thrombosis of both
emoral veins. The right femoral artery was mainly used for
he procedure; however, in eight patients both arteries were
annulated. Transesophageal echocardiography was used to
uide the procedure in 32 (91%) and/or ICE in 5 (14%)
atients. Device placement was successful in 32 patients
91%). Three patients failed the attempt, and their devices
ere retrieved because of significant device-related aortic
egurgitation in two and inability to achieve a good device
igure 2. Transesophageal echocardiographic images of the same patient a
eptal defect (VSD) with aneurysm formation (arrow). (B) Short-axis view
he arteriovenous loop passing from the aorta through the VSD to the righ
entricular apex. (E) The left ventricular disk is deployed. (F) Short-axis
our-chamber view indicates good device position. (H) Color Doppler map
trium; LV  left ventricle; RV  right ventricle.osition in one. The median VSD size was 7 mm (range, 4 co 15 mm), and the median device size used was 10 mm
range, 6 to 16 mm). The median fluoroscopy time was 36
in (range, 14 to 191 min), and the median total procedure
ime was 121 min (range, 67 to 276 min). A VSD with
neurysm formation was noted in 45.7% (16 of 35) of our
atients. Two of them had multiple fenestrations.
ollow-up data. Table 2 summarizes the data before and
fter device insertion, including presence of heart murmur,
lectrocardiogram, chest radiograph, and echocardiographic
ssessment of shunt status, size of the left atrium and
entricle, and presence or absence of valvar regurgitation.
he complete closure rate increased from 20 of 32 at 24 h
fter the procedure to 27 of 28 at six-month follow-up.
urthermore, as noted in Table 2, aortic regurgitation (AR)
as present in 9 of 35 (25.7%) patients before closure (6
ith trivial and 3 with mild AR). At discharge, 17 of 32
53.1%) patients had AR (11 with trivial and 6 with mild
R). At one-month follow-up, 15 of 32 (46.9%) patients
ad AR (10 with trivial and 5 with mild AR), and at
ix-month follow-up, 11 of 28 (39.3%) patients had AR (7
ith trivial and 4 with mild AR). Because of the small
ample size in each category of AR, we were unable to
redict who would develop or have an increase in the
everity of AR. Data for the tricuspid and mitral valves are
hown in Table 2.
omplications. Serious adverse events were encountered
n three (8.6%) patients. In one patient (a two-year-old girl;
eight, 9.1 kg; with a 6-mm PmVSD with left-sided
igure 1. (A) Four-chamber view showing the perimembranous ventricular
color Doppler at the subaortic level showing the shunt. (C) The wire of
um (RA). (D) Four-chamber view showing the delivery sheath in the left
showing good device position before its release. (G) Final image in the
showing no residual shunt with a trivial tricuspid regurgitation. LA  lefts in F
with
t atri
viewhamber enlargement requiring anti-congestive medica-
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January 17, 2006:319–25 Transcatheter Closure of Perimembranous VSDions; increased vascular markings on chest radiograph)
here developed a complete heart block with intermittent
econd-degree atrioventricular block approximately 2 h after
n 8-mm device was implanted without any difficulty. The
omplete heart block persisted with few symptoms despite
reatment with a course of corticosteroids. A permanent
acemaker was implanted three months after the closure.
ne patient who underwent the attempt using the trans-
epatic approach experienced peri-hepatic bleeding requir-
ng blood transfusion. Finally, transcatheter device retrieval
ailed in a three-year-old boy; weight, 8 kg; with a 7.5-mm
mVSD with left ventricular and left atrial enlargement.
he procedure was performed in routine fashion, and a
0-mm device was implanted. Before device release, TEE
id not show any AR; however, after device release, ascend-
ng aortography showed moderate to severe aortic insuffi-
iency. Device removal was attempted using a biopsy
orceps. The device was pulled into the right ventricle;
owever, it was entangled in the tricuspid valve apparatus
nd the retrieval was abandoned because of increased
ricuspid insufficiency. The child was sent to the operating
oom for device retrieval and VSD closure. At operation,
he right atrium was opened and the device was seen
rotruding through the anterior leaflet of the tricuspid valve.
he device was removed, the tricuspid valve apparatus was
epaired, and the VSD was closed. The child has done very
ell without any complication, including absence of aortic
r tricuspid regurgitation. Adverse events developed in 15
atients, including 2 patients in whom hemolysis developed
nd improved without transfusion, 2 patients with femoral
ematoma, and one patient each with right bundle branch
lock, fever, transient hypotension, transient bradycardia,
able 2. Data Before and After Implantation of the Amplatzer M
Before Implantation 10 m
urmur 100% (35/35)
CG
LVH 38.2% (13/34)
LAE 11.8% (4/34)
XR
Cardiomegaly 54.3% (19/35)
chocardiography n  3
Complete closure 15
Trivial shunt 7
Small shunt 9
Moderate shunt 1
Large shunt 0
LAESD (mean  SD, Z score) 3.4  2.1 (n  32)
LVEDD (mean  SD, Z score) 1.8  1.7 (n  32)
AR 25.7% (9/35) 37.5% (1
TR 74.3% (26/35) 81.3% (2
MR 34.3% (12/35) 28.1% (9
p  0.05 compared with the pre-device closure data. †The remaining four patients w
AR  aortic regurgitation; CXR  chest X-ray; ECG  electrocardiography; LA
entricular end-diastolic dimension; LVH  left ventricular hypertrophy; MR  mransient ventricular tachycardia, left bundle branch block, emesis, migraine, trivial AR, mild-moderate tricuspid re-
urgitation, and bleeding.
ISCUSSION
he Amplatzer Membranous VSD Occluder (AGA Med-
cal Corp.) is the only device specifically designed for closure
f PmVSDs. It has the following advantages. First, it is an
symmetric device with a short aortic end of the left
entricular disk, thereby avoiding potential impingement on
he aortic valve. A special pusher catheter that has a metal
apsule at its end facilitates orientation of the device in the
orrect position. Second, the operator has full control and
an recapture and redeploy the device before release should
he device be deployed in the wrong position or location.
hird, the high closure rates achieved with this device are
ttributable to the mechanism of closure (stenting the defect
ith the waist). This is one of the reasons that it can achieve
better complete closure rate than other devices (90% to
00% vs. 25% to 60%) (6–16). Fourth, the device requires a
mall delivery sheath (7- to 9-F) for deployment; this makes
t easily applicable to smaller children. Fifth, it is round in
hape without the corners or spokes that have potential risks
f immediate or delayed injury of valves or tissues.
Because the membranous septum is very thin, the oper-
tor may not feel any resistance during device pullback from
he left ventricle to the septum. As a result, the device might
e misplaced in the right ventricle. Therefore, echocardiog-
aphy (TEE or ICE) and angiography are crucial to identify
orrect device deployment. In addition, echocardiography
an recognize immediate possible adverse events of AR
aused by impingement of the device on the valve leaflets
nd mitral or tricuspid regurgitation caused by the interfer-
ranous VSD Occluder
After Implantation
24 h 1 month 6 months
53%* (17/32) 53%* (17/32) 35.7%* (10/28)
34.4% (11/32) 25.0% (8/32) 25.9% (7/27)
0 (0/31) 0 (0/32) 0 (0/27)
40.6% (13/32) 24%* (6/25) 16.7% (2/12)
n  32 n  32 n  28†
20 25 27
4 2 1
6 4 0
1 0 0
1 1 0
2.7  1.7 (n  32) 2.5  1.7* (n  30) 2.2  2.0* (n  27)
1.3  1.9 (n  31) 0.7  1.5* (n  30) 0.6  1.8* (n  25)
53.1% (17/32) 46.9% (15/32) 39.3% (11/28)
78.1% (25/32) 65.6% (21/32) 69.2% (18/26)
31.3% (10/32) 12.5%* (4/32) 18.5% (5/27)
not make the follow-up at 6 months had complete closure at the 30-day follow-up.
 left atrial end-systolic dimension; LAE  left atrial enlargement; LVEDD  left
gurgitation; TR  tricuspid regurgitation.emb
in
2
2/32)
6/32)
/32)
ho didnce with the chordae tendineae.
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Transcatheter Closure of Perimembranous VSD January 17, 2006:319–25Our results showed that presence of an aneurysm did not
revent device closure. If the aneurysm was large and the
pening was solitary, the device could be accommodated
ithin the aneurysmal sac, away from the aortic valve,
hereby preventing AR (9). In most situations, the device
as placed in the usual septal position (Figs. 1 and 2).
This series reports the largest cohort of patients with
mVSDs who underwent transcatheter closure using the
ew Amplatzer Membranous VSD Occluder (AGA Med-
cal Corp.). The successful procedure rate was 91%. The
omplete closure rate was excellent, 96% at six months after
he procedure, with the remaining 4% (one patient) having
nly trivial residual shunt.
The left atrial and ventricular sizes decreased after the
rocedure. Both left atrial and ventricular dimensions
chieved a significant decrease in the Z score at 30 days and
ix months (Table 2). This indicates that the device was
ffective in abolishing the left-to-right shunt that resulted in
decrease in the left heart chambers. Mitral and tricuspid
egurgitation improved in some patients after the procedure.
he proportion of mitral regurgitation decreased from
4.3% before device implantation to 12.5% at one-month
ollow-up. This again indicated that patients benefited from
limination of the shunt.
No mortality, stroke, or neurologic deficit was noted in
ur series. This compares favorably to the current surgical
esults for isolated PmVSDs (4,5).
Hobbins et al. (18) reported that complete right bundle
ranch block occurred in 79% and 33% of patients after
urgical repair of VSD through the right atrium or right
entricle approach, respectively. Yeager et al. (3) reported
hat 75.3% of patients had persistent postoperative conduc-
ion abnormality including complete heart block (2.3%),
omplete right bundle branch block (64%), and bifascicular
lock (9%). However, patients who were in that study (3)
ere younger than one year of age; therefore, direct com-
arison with our series of patients, who were older, should
e viewed with caution. The current study found that
undle branch block occurred in only 6% of patients (2 of
2) who underwent device closure. Permanent complete
eart block requiring a pacemaker developed in one patient.
The development of AR is an important concern for
evice closure of PmVSDs. In the 32 patients undergoing
evice closure, new trivial AR without clinical or hemody-
amic significance within 24 h developed in 5 patients
15.6%), and new mild AR within 24 h developed in 3
atients (9%), for a total of 17 of 32 (53%) patients with AR
Table 2). This might be related to the configuration change
f the subaortic septum or repeated crossing of the aortic
alve by catheters and guidewires. At six-month follow-up,
1 of 28 (39%) patients had AR. This indicates that some of
he aortic regurgitation was transient.
tudy limitations. The patients in our study were larger
nd older than those in whom surgical closure of a VSD is
onsidered. The application of the Amplatzer Membranous
SD Occluder (AGA Medical Corp.) in small infants may
1arry a higher risk and remains to be determined. Our
ollow-up period was only six months. The preliminary
esults and possible delayed adverse effects, including heart
lock, need to be confirmed by a larger trial and by
ong-term follow-up.
onclusions. Transcatheter closure of PmVSDs using the
mplatzer Membranous VSD Occluder (AGA Medical
orp.) is technically feasible and seems safe enough in larger
hildren to warrant continuation of clinical trials to assess
he long-term safety and efficacy of this device.
DDENDUM
ince the acceptance of this paper, one more patient
eveloped complete heart block 16 months after device
losure requiring pacemaker implantation.
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